Virtual Patient: Care of an Older Adult with Immune Deficiency During the COVID-19 Pandemic

In this patient simulation, you will evaluate and treat a patient with Common Variable Immune Deficiency (CVID) during the COVID-19 pandemic. You will learn about risk factors for severe COVID-19 disease in general and will examine available literature regarding COVID-19 in immune deficient patients. Strategies to prevent exposure to SARS-COV-2 in general will be discussed, with a focus on issues unique to immune deficient patients such as potential disruption or changes in infusion therapies in order to promote social distancing. The mechanisms by which SARS-COV-2 infects and inflicts damage upon host cells will be briefly explored, with a focus on why immune deficient patients may have a more difficult time fighting the virus. You will also learn about the current treatment for COVID-19 in otherwise healthy patients and in patients with a compromised immune system.    

This course is funded by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

  • Allergist/immunologists
  • Fellows-in-Training
  • Nurses and Nurse Practitioners
  • Physician Assistants and Other Allied Health Professionals

Learning Objectives

Upon completion of this course, the learner will be able to:

  1. Summarize risk factors for more severe COVID-19 disease, including what is known regarding the risk of severe disease in immune deficient patients
  2. Identify strategies to prevent exposure to SARS-COV-2 among immune deficient patients
  3. Discuss the treatment of COVID-19 in general, and caveats for treatment of immune deficient patients with COVID-19
Summary
Available credit: 
  • 0.75 Attendance
    Attendance credit.
  • 0.75 CME
    CME credit.
Course opens: 
10/14/2020
Course expires: 
12/31/2022
Cost:
$0.00
Rating: 
3.5
PLANNING COMMITTEE

Tolly Epstein, MD FAAAAI
University of Cincinnati School of Medicine and Allergy Partners of Central Indiana, Cincinnati, OH
Relevant relationships: None

Anil Nanda, MD FAAAAI
Asthma and Allergy Center, Lewisville and Flower Mound, TX and University of Texas-Southwestern Medical Center, Dallas, TX
Relevant relationships: None

FACULTY

Rohit Divekar, MBBS PhD
Mayo Clinic, Rochester, MN
Relevant relationships: None

Dennis K. Ledford, MD FAAAAI
University of South Florida College of Medicine and the Veterans Administration
Relevant relationships: Speaker: ALK (Topic/Product: allergic rhinitis/allergen immunotherapy); AstraZeneca (Topic: Asthma/Benralizumab); Boehringer Ingelheim (Topic/Product: COPD and asthma/tiotroprium); Genentech (Topic: Urticaria and asthma/omalizumab); Novartis (Topic: Urticaria, asthma); Sanofi/Regneron (Asthma)
Research Grant: AstraZeneca; Topic/Product: Severe asthma
Consultant: Genentec: Teaching slide development; AstraZeneca (Topic: Asthma)

Brittanie Neaves, MD
SAUSHEC/ Wilford Hall/ United States Air Force
Relevant relationships: None

Sharmilee M. Nyenhuis, MD FAAAAI
University of Illinois at Chicago
Relevant relationships: Sanofi Advisory Board

Christopher C. Randolph, MD FAAAAI
Yale University
Relevant relationships: Speaker: Boehringer Ingelheim (Topic/Product: Spiriva); Ista (Topic/Product: Pharmaceutical products); Sunvirion (Topic/Product: Pharmaceutical products); Optinose (Topic/Product: Xhance)
Research Grant: AstraZeneca (Topic/Product: Pearl study/ANDHI Benralizumab study); ALK (Topic/Product: ALK protocolMT-11/233669:ALK-Abello A/S mite SLIT in children and adolescents)
Consultant: Merck (Topic/Product: Singulair)
Honorarium/Gift: TEVA speaker,consultant,research grant (Topic/Product: Qvar/Proair); Meda speaker honorarium (Topic/Product: Dymista)
Advisory Board: Shire speaker (Topic/Product: Lanadelumab); GSK (Topic/Product: Nucala); Pharma (Topic/Product: Ruconest)
Owner of EVH unit purchased from Dr Richard Rosenthal exhibitor of EVH units (Topic/Product: EVH)

Marissa Shams, MD
Emory University School of Medicine
Relevant relationships: None

Andrew Smith, MD
Allergy Associates of Utah
Relevant relationships: None

Kathleen E. Sullivan, MD PhD FAAAAI
Children's Hospital Of Philadelphia
Relevant relationships: None

Richard L. Wasserman, MD PhD FAAAAI
Allergy Partners of North Texas
Relevant relationships: Consultant: ADMA Biologics, Gerson Lehman Group, Guidepoint Global, Korean Green Cross, LEK, Takeda, Therapure
Speaker: CSL Behring, National Association of Managed Care Physicians, Takeda, The Problem Based Learning Institute

CONTENT REVIEWERS

Gloria Akan, MD
ENTAA Care, Glen Burnie, MD
Relevant relationships: None

Brian Kelly, MD 
St. Paul Allergy and Asthma, St. Paul, MN
Relevant relationships: None

Todd Rambasek, MD FAAAAI
ENT Allergy & Health Services, Westlake, OH
Relevant relationships: None

ACCREDITATION STATEMENT

The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT

The American Academy of Allergy, Asthma & Immunology designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CREDIT CLAIMING PERIOD

Credit claiming for this activity will expire at 11:59 pm on October 13, 2022. Requests to claim credit on or after October 13, 2022 will be subject to an administrative fee.

AAAAI PRIVACY POLICY

To verify your participation in educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at cme@aaaai.org.

QUESTIONS

Activity related questions should be directed to cme@aaaai.org. 

Available Credit

  • 0.75 Attendance
    Attendance credit.
  • 0.75 CME
    CME credit.

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari.

Internet Explorer is no longer supported.